dostarlimab Report issue

Biologics mAb Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA
AACT

Active Ingredient History

NOW
  • Now
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

tsr-042

Organizations (45)

Research & Development (45)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (31)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (31)


 

Biliary Tract Neoplasms (Phase 2)

BRCA1 Protein (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Homologous Recombination (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Mutation (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 3)

Ovarian Diseases (Phase 3)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 1/Phase 2)

Sarcoma, Clear Cell (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 44
  • # of Trial Organizations: 45

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue